Investigation Report on China ribonucleic acid II (RNAII) for Injection, 2010-2019
RNAII for injection, one kind of immunomodulator, can improve body immunity and inhibit tumor by causing vacuolar degeneration and colliquative necrosis in tumor cells as well as generating large amounts of hyperplastic fibroblasts, macrophages, lymphocytes or even connective tissue to substitute tumor tissue. And it is used for the adjuvant treatment of pancreatic cancer, liver cancer, stomach cancer, breast cancer, soft tissue sarcoma and other cancers especially hepatitis B. RNAII for injection can also be used for the treatment of various diseases caused by low immune function.
According to CRI’s market survey, RNAII for injection develops fast in China with sales value rising from less than CNY 60 million in 2005 to about CNY 500 million in 2014 and CAGR during this period reaching 80%.
With the lifestyle changes brought about by economic development as well as the serious environmental pollution, the incidence of cancer keeps increasing with the number of new cases exceeding 3 million each year in China. Meanwhile, there are over 90 million hepatitis B patients in China too. Therefore, the market size of RNAII for injection is expected to keep growing in the next few years in China.
Readers can get at least the following information from this report:
market size of RNAII for injection in China
competitive landscape of RNAII for injection in Chinese market
price of RNAII for injection made by different enterprises in China
market outlook of RNAII for injection in China
suggests the following groups of people purchase this report:
manufacturers of immunomodulator
investors/ research institutions interested in Chinese medicine market
any interest in the Chinese medicine market, please contact CRI for customized survey service
Jilin Aodong Pharmaceutical Industry Group Yanji Co., Ltd; Nanjing Xinbai Pharmaceutical Co., Ltd; Xinxiang Dongsheng Pharmaceutical Co., Ltd